Improved stratification procedures may facilitate more efficient therapeutic trials in AD, based not only on neuro inflammation, tau, atrophy, or connectivity, but on their complex interaction that leads to individual differences in cognitive impairment. The gene discussed is MAPT; the disease is Alzheimer disease.